All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answered: Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?
Welcome to the Multiple Myeloma Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of the treatment of multiple myeloma and its precursor states.
In this presentation, Mateos discusses the progression of monoclonal gammopathy of undetermined significance (MGUS) and SMM to MM from a molecular point of view. She explains the 2/20/20 risk stratification model for SMM, and the phase III clinical trials that have demonstrated a benefit in treating patients with high-risk SMM to delay the progression to overt MM. In her road map to cure MM, early treatment of SMM is a crucial step, and she presents two curative approaches being currently investigated in clinical trials.
Is the treatment of high-risk SMM the way for achieving the cure?
María-Victoria Mateos' slides are available as a downloadable resource below.Download the slides here!
Find below links to the other talks from the symposium:
'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.
'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.
'Treating elderly and frail patients with MM: Cure versus disease control' presented by Vincent Rajkumar.
'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.
Daratumumab for smoldering multiple myeloma — results from the phase II CENTAURUS study
Report from phase II, open-label CENTAURUS study investigating the efficacy and safety of three daratumumab dosing schedules for patients with smoldering multiple...
Smoldering multiple myeloma (SMM): an introduction to this month’s educational theme on the multiple myeloma (MM) Hub
Starting July 2019, the Multiple Myeloma (MM) Hub will be featuring articles centered around an educational theme. This article on...
Subscribe to get the best content related to multiple myeloma delivered to your inbox